No Interaction Expected
Emtricitabine/Tenofovir-DF (FTC/TDF, PrEP)
Quality of Evidence: Very Low
Coadministration of emtricitabine/tenofovir-DF and rifampicin alone has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as rifampicin is deacetylated. Coadministration of tenofovir-DF and rifampicin decreased tenofovir AUC, Cmax and Cmin by 12%, 16% and 15%, respectively. Coadministration of TB treatment containing rifampicin (with ethambutol, isoniazid and pyrazinamide) and emtricitabine/tenofovir-DF (with efavirenz) decreased rifampicin Cmax by 14%. Emtricitabine AUC and Cmin increased by 5% and 26% and Cmax decreased by 3%. Tenofovir AUC and Cmin increased by 13% and 9% and Cmax decreased by 2%. No dose adjustment is necessary.